Abstract 228P
Background
Recent research has emphasized the pivotal role of tumor-associated macrophages (TAMs) in shaping the efficacy of anti-tumor therapies. Metabolic reprogramming is a key driver of TAM polarization, influencing their pro-tumorigenic or anti-tumorigenic phenotypes. However, the precise mechanisms by which tumor cells manipulate TAM metabolism remain elusive. We have currently discovered that agonistic anti-CD40 antibodies promote anti-tumorigenic TAM activation by enhancing mitochondrial activity and modulating fatty acid oxidation (FAO). We further investigated the interplay between mitochondrial fitness and FAO in regulating TAM immunosuppressive functions.
Methods
We conducted a series of in vitro and in vivo experiments using mouse melanoma tumor models and bone marrow-derived macrophages (BMDMs) for this study.
Results
Our findings demonstrate that lipid-accumulated TAMs exhibit impaired mitochondrial activity, exacerbating their pro-tumorigenic properties. Tumor-derived lipids influence mitochondrial dynamics in TAMs, leading to increased FAO, mitochondrial reactive oxygen species (mtROS) production, and mitophagy. These metabolic alterations collectively contribute to the pro-tumorigenic phenotype of TAMs. Moreover, our research suggests that targeting mitochondrial dynamics-associated pathways may represent a promising therapeutic strategy to reverse TAM immunosuppression and enhance anti-tumor immunity.
Conclusions
This study provides valuable insights into the intricate relationship between lipid metabolism, mitochondrial dynamics, and TAM polarization within the tumor microenvironment (TME). By elucidating how lipid metabolism interacts with mitochondrial dynamics to modulate TAM phenotypes, we aim to develop innovative therapeutic approaches targeting these pathways to improve anti-tumor responses.
Legal entity responsible for the study
The author.
Funding
National Science and Technology Council (MOST 111-2314-B-400-026-MY3).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session